The dark side of antihormonal action in breast cancer

Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets

Volumn , Issue , 2009, Pages 63-83

  Gee, Julia M W ^a   Stone, Andrew ^a   McClelland, Richard A ^a   Hiscox, Stephen ^a   Hutcheson, Iain R ^a   Jordan, Nicola J ^a   Fiegl, Heidi M ^b   Widschwendter, Martin ^c   Shaw, Victoria E ^a   Barrow, Denise ^a   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antihormone; Compensatory signalling; Microarray; Resistance; Tumour suppressor

Indexed keywords

EID: 84860394589     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-8526-0_4     Document Type: Chapter

References (108)

1. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF (2005) Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12:S135-S144
2. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R (2007) Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multi-Agent HER-Targeted therapy. J Natl Cancer Inst 99:694-705
3. Arpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29:217-233
4. Badia E, Duchesne MJ, Semlali A, Fuentes M, Giamarchi C, Richard-Foy H, Nicolas JC, Pons M (2000) Long-Term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 60:4130-4138
5. Bates NP, Hurst HC (1997) An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 15:473-481
6. Bates RC, Edwards NS, Burns GF, Fisher DE (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/akt in colon carcinoma cells. Cancer Res 61:5275-5283
7. Borley AC, Barrett-Lee PJ, Gee JMW, Shaw V, Nicholson RI, Hiscox SE (2007) Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells. Breast Cancer Res Treat 106:S1, 24
8. Bos JL, Rehmann H, Wittinghofer A (2007) GEFs and GAPs: Critical elements in the control of small g proteins. Cell 129:865-877
9. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI (2006) Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96:131-146
10. Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang TH (2008) Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res 68:1786-1796
11. Cheung KL, Willsher PC, Pinder SE, Ellis IO, Elston CW, Nicholson RI, Blamey RW, Robertson JF (1997) Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat 45:219-224
12. Chia S, Gradishar W (2008) Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. Breast 17:S16-S21
13. Cunliffe HE, Ringner M, Bilke S, Walker RL, Cheung JM, Chen Y, Meltzer PS (2003) The gene expression response of breast cancer to growth regulators: Patterns and correlation with tumour expression profiles. Cancer Res 63:7158-7166
14. Demirpence E, Semlali A, Oliva J, Balaguer P, Badia E, Duchesne MJ, Nicolas JC, Pons M (2002) An estrogen-responsive element-Targeted histone deacetylase enzyme has an antiestrogen activity that differs from that of hydroxytamoxifen. Cancer Res 62:6519-6528
15. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR (2001) Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 92:404-408
16. Dunn M, Sinha P, Campbell R, Blackburn E, Levinson N, Rampaul R, Bates T, Humphreys S, Gullick WJ (2004) Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J Pathol 203:672-680
17. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP (2006) Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66:11954-11966
18. Fan P, Wang J, Santen RJ, Yue W (2007) Long-Term treatment with tamoxifen facilitates translocation of estrogen receptor alpha Out Of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 67:1352-1360
19. Fersis N, Smyczek-Gargya B, Armeanu S, Gagulic E, Pantic L, Relakis K, Friedrich M, Wallwiener D (2004) Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer. Eur J Gynaecol Oncol 25:45-50
20. Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M, Jacquemier J, Viens P, Birnbaum D, Bertucci F (2008) Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res 68:767-776
21. Fox BP, Kandpal RP (2004) Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318:882-892
22. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up-And down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574
23. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS (2004) Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-1533
24. Gee JM, Hutcheson IR (2005) Understanding endocrine resistance: The critical need for sequential samples from clinical breast cancer and novel in vitro models. Breast Cancer Res Treat 7: 187-189
25. Gee JM, Willsher PC, Kenny FS, Robertson JF, Pinder SE, Ellis IO, Nicholson RI (1999) Endocrine response and resistance in breast cancer: A role for the transcription factor fos. Int J Cancer 84:54-61
26. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI (2003) The anti-epidermal growth factor receptor agent gefitinib (ZD1839/iressa) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144:5105-5117
27. Gee J, Shaw V, Burmi R, McClelland R, Morgan H, Harper M, Hiscox S, Barrow D, Lewis P, Nicholson R (2004) Array profiling of survival and resistance genes in anti-hormone-Treated breast cancer cells. Intl J Mol Med 14:S81
28. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI (2005a) Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12:S99-S111
29. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, Johnston Jones SRHE, Wakeling AE, Duncan R, Nicholson RI (2005b) Consensus statement. Workshop on therapeutic resistance in breast cancer: Impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer 12:S1-S7
30. Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI (2006) Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer 13:S77-S88
31. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, Weinstein I, Reuveni H, Ben-Sasson SA (2004) Lyn is a target gene for prostate cancer: Sequence-based inhibition induces regression of human tumour xenografts. Cancer Res 64:1058-1066
32. Guasch RM, Scambler P, Jones GE, Ridley AJ (1998) RhoE regulates actin cytoskeleton organization and cell migration. Mol Cell Biol 18:4761-4771
33. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M (2005) Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-Activated protein kinase. J Clin Oncol 23:2469-2476
34. Harper ME, Smith C, Nicholson RI (2005) Upregulation of CD44s and variants in anti-hormone resistant breast cancer cells. Eur J Cancer 3:A71
35. Higgins KJ, Liu S, Abdelrahim M, Vanderlaag K, Liu X, PorterW, Metz R, Safe S (2008) Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/sp proteins. Mol Endocrinol 22:388-402
36. Hiscox S, Morgan L, Barrow D, Dutkowski C, Wakeling A, Nicholson RI (2004) Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile & invasive phenotype: Inhibition by gefitinib (iressa, ZD1839). Clin Exp Metastasis 21:201-212
37. Hiscox S, JiangWG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI (2006a) Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 118:290-301
38. Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI (2006b) Chronic exposure to fulvestrant promotes overexpression of the c-met receptor in breast cancer cells: Implications for tumour-stroma interactions. Endocr Relat Cancer 13:1085-1099
39. Hiscox S, Borley A, Barratt-Lee P, Jordan NJ, Gee J, Shaw V, McClelland R, Nicholson RI (2006c) Tamoxifen promotes cellular invasion in intercellular-Adhesion deficient breast cancer cells. J Steroid Biochem Mol Biol 76(1-5):154
40. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI (2006d) Elevated src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97:263-274
41. Hiscox S, Green TP, Smith C, James M, Jordan N, Nicholson RI (2007) Combination therapy with AZD0530 and tamoxifen prevents acquired anti-oestrogen resistance in breast cancer cells. Proc Am Assoc Can Res Molecular Targets and Cancer Therapeutics Meeting A231
42. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, Walker CL (2003) Tamoxifen functions as a molecular agonist inducing cell cycle-Associated genes in breast cancer cells. Mol Cancer Res 1:300-311
43. Holloway JN, Murthy S, El-Ashry D (2004) A cytoplasmic substrate of mitogen-Activated protein kinase is responsible for estrogen receptor-Alpha down-regulation in breast cancer cells: The role of nuclear factor-b. Mol Endocrinol 18:1396-1410
44. Howell A (2006) Fulvestrant (faslodex): Current and future role in breast cancer management. Crit Rev Oncol Hematol 57:265-273
45. Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI (2007) Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 9:R50
46. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S (2002) Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinology 29:175-192
47. Johnston SR, Leary A, Martin LA, Smith IE, Dowsett M (2008) Enhancing endocrine response with novel targeted therapies: Why have the clinical trials to date failed to deliver on the preclinical promisé Cancer 112:710-717
48. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163-167
49. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:793-814
50. Kaipparettu BA, Malik S, Konduri SD, LiuW, RokavecM, van der Kuip H, Hoppe R, Hammerich-Hille S, Fritz P, Schroth W, Abele I, Das GM, Oesterreich S, Brauch H (2008) Estrogenmediated downregulation of CD24 in breast cancer cells. Int J Cancer 123:66-72
51. Kalaitzidis D, Gilmore TD (2005) Transcription factor cross-Talk: The estrogen receptor and NFkappaB. Trends Endocrinol Metab 16:46-52
52. Kenny FS, Willsher PC, Gee JM, Nicholson R, Pinder SE, Ellis IO, Robertson JF (2001) Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res Treat 65:135-144
53. Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE (2008) B-RAF regulation of rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell 19:498-508
54. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistantMCF-7 cells. Endocrinology 144:1032-1044
55. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI (2005) Insulin-like growth factori receptor signalling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146:4609-4618
56. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW (1998) Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 95:2920-2925
57. Levenson AS, Kliakhandler IL, Svoboda KM, Pease KM, Kaiser SA, Ward JE 3rd, Jordan VC (2002a) Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha. Br J Cancer 87:449-456
58. Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA, Jordan VC (2002b) Gene expression profiles with activation of the estrogen receptor alphaselective estrogen receptor modulator complex in breast cancer cells expressing wild-Type estrogen receptor. Cancer Res 62:4419-4426
59. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, Nephew KP, Huang TH (2004) Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 64:8184-8192
60. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934
61. Maynadier M, Nird́e P, Ramirez JM, Cathiard AM, Platet N, Chambon M, Garcia M (2008) Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells. Adv Exp Med Biol 617:485-491
62. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI (2001) Enhanced epidermal growth factor receptor signalling in MCF-7 breast cancer cells after long-Term culture in the presence of the pure antiestrogen ICI 182,780 (faslodex). Endocrinology 142:2776-2788
63. McKeage K, Perry CM (2002) Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62:209-243
64. Miller WR, Larionov A, Anderson TJ, Walker JR, Krause A, Evans DB, Dixon JM (2008) Predicting response and resistance to endocrine therapy: Profiling patients on aromatase inhibitors. Cancer 112:689-694
65. Miyamoto K, Ushijima T (2005) Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 35:293-301
66. Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A, Nol̀e F (2006) Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8:R4
67. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: Understanding resistance to HER2-Targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280
68. Newman SP, Bates NP, Vernimmen D, ParkerMG, Hurst HC (2000) Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19:490-497
69. Nicholson RI, Johnston SR (2005) Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat 93:S3-S10
70. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM (2004) Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: New opportunities for therapy. Endocr Relat Cancer 11:623-641
71. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM (2005) Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: The use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 12:S29-S36
72. Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, Gee JM (2007) Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord 8:241-253
73. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F, NCINaple Breast Cancer Group (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721-747
74. Oliva J, El Messaoudi S, Pellestor F, Fuentes M, Georget V, Balaguer P, Cavaill̀es V, Vignon F, Badia E (2005) Involvement of HP1alpha protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cells. FEBS Lett 579:4278-4286
75. Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M (2000) Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Molecular Endocrinol 14:999-1009
76. Platet N, Cathiard AM, Gleizes M, Garcia M (2004) Estrogens and their receptors in breast cancer progression: A dual role in cancer proliferation and invasion. Critical Reviews Oncol/Hematol 51:55-67
77. Ponta H, Sherman L, Herrlich PA (2003) CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33-45
78. Powers MV, Workman P (2006) Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13:S125-S135
79. Pratt MA, Bishop TE, White D, Yasvinski G, Menard M, Niu MY, Clarke R (2003) Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: Roles in growth and hormone independence. Mol Cell Biol 23:6887-6900
80. Rajendran RR, Nye AC, Frasor J, Balsara RD, Martini PG, Katzenellenbogen BS (2003) Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97). J Biol Chem 278:4628-4638
81. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO (2005) E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 46:685-693
82. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO (2008) Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer 44:73-83
83. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM (2004) ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 6:1-6
84. Riento K, Villalonga P, Garg R, Ridley A (2005) Function and regulation of RhoE. Biochem Soc Trans 33:649-651
85. Riggins RB, Zwart A, Nehra R, Clarke R (2005) The nuclear factor kappa b inhibitor parthenolide restores ICI 182,780 (faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 4:33-41
86. Shaw VE, Gee JMW, McClelland RA, Morgan H, Rushmere N, Nicholson RI (2005) Identification of anti-hormone induced genes as potential therapeutic targets in breast cancer. Proc Amer Assoc Cancer Res 46:A3706
87. Shou J, Massaraweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-Talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935
88. Staka CM, Nicholson RI, Gee JM (2005) Acquired resistance to oestrogen deprivation: Role for growth factor signalling kinases/oestrogen receptor cross-Talk revealed in new MCF-7x model. Endocr Relat Cancer 12:S85-S97
89. Stein B, Yang MX (1995) Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa b and C/EBP beta. Mol Cell Biol 15:4971-4979
90. Stone A, Jones H, Giles M, Gee J, Nicholson R (2008) Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity. Breast Cancer Res 10:P41
91. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS (2006) Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. J Biol Chem 281:16272-16278
92. Suzuki T, Shoji S, Yamamoto K, Nada S, Okada M, Yamamoto T, Honda Z (1998) Essential roles of lyn in fibronectin-mediated filamentous actin assembly and cell motility in mast cells. J Immunol 161:3694-3701
93. Townsend PA, Stephanou A, Packham G, Latchman DS (2005) Bag-1: A multi-functional prosurvival molecule. Int J Biochem Cell Biol 37:251-259
94. Treeck O, Zhou R, Diedrich K, Ortmann O (2004) Tamoxifen long-Term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells. Anticancer Drugs 15:787-793
95. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R (2003) Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 22:761-768
96. Valentine JE, Kalkhoven E, White R, Hoare S, Parker MG (2000) Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J Biol Chem 275:25322-25329
97. Van Agthoven T, van Agthoven TL, Dekker A, Foekens JA, Dorssers LC (1994) Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol 8:1474-1483
98. Vieth M, Sutherland JJ, Robertson DH, Campbell RM (2005) Kinomics: Characterizing the therapeutically validated kinase space. Drug Discov Today 10:839-846
99. Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21:5462-5482
100. Wilson MA, Chrysogelos SA (2002) Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. J Cell Biochem 85:601-614
101. Wu JT, Kral JG (2005) The NF-kappaB/IkappaB signaling system: A molecular target in breast cancer therapy. J Surg Res 123:158-169
102. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ (2008) Association between imatinib-resistant BCR-ABL mutationnegative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100:926-939
103. Wu M, Soler DR, Abba MC, NunezMI, Baer R, Hatzis C, Llombart-Cussac A, Llombart-Bosch A, Aldaz CM(2007) CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer. Mol Cancer Res 5:1285-1295
104. Yarden RI, Wilson MA, Chrysogelos SA (2001) Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth. J Cell Biochem 81:232-246
105. Ye Y, Xiao Y, WangW, Yearsley K, Gao JX, Barsky SH (2008) ERalpha suppresses slug expression directly by transcriptional repression. Biochem J 416(2):179-8
106. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC (2005) The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12:S37-S46
107. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC (2007) Enhanced NF kappa b and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7:59
108. Zubairy S, Oesterreich S (2005) Estrogen-repressed genes-key mediators of estrogen actioń Breast Cancer Res 7:163-16